EP. 10 Real-World Evidence on Use of Immune Checkpoint Inhibitor Combinations and Clinical Trial Endpoints
November 17th, 2026Long-Term SANO Data Reinforce Active Surveillance as an Option in Esophageal Cancer Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.Read more
November 16th, 2026Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic CancerThe European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.Read more
November 16th, 2026Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRCOnvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.Read more
November 12th, 2026GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.Read more
November 8th, 2026Five Under 5: Top Oncology Videos for the Week of 11/1The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.Read more
November 6th, 2026Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.Read more
November 17th, 2026Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLCThe CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.Read more
November 17th, 2026FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System LymphomaThe FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.Read more